Advanced Cancer Therapeutics (ACT) has received Phase I small business innovative research (SBIR) grant of $158,000 from the National Cancer Institute of the National Institutes of Health (NIH) to support the development of an anti cancer ...
Tags: ACT, SBIR Grant, anti cancer drug, Anticancer Drug
VentiRx Pharmaceuticals has formed a world-wide collaboration with Celgene Corporation to develop VTX-2337, a highly potent and selective TLR8 agonist for cancer treatment. As part of the agreement, Celgene will fund $35m as upfront ...
Clinical stage biopharmaceutical company, Tocagen, has entered into a partnership agreement with MRI Interventions and Brainlab. Under the collaboration, Tocagen will use MRI Interventions' ClearPoint neuro intervention system at selected ...
Results are interesting for treating skin cancer(melanoma)and nervous system tumors,known as gliomas. "Promising results"-Pablo Botella,researcher at the Institute of Chemical Technology of Valencia. Spanish researchers have ...
Hospira has recalled 9 lots of cancer drugs including carboplatin, cytarabine, paclitaxel, and methotrexate packaged in vials in the US. The recall, which is based on the appearance of visible particles embedded in the glass located at ...
Tags: Recall, Cancer Drug, FDA
Dako, a Danish provider of cancer diagnostics solutions, has received approval from the US Food and Drug Administration to market HercepTest and HER2 FISH pharmDx Kit as companion diagnostics for pertuzumab (Perjeta) - a new Genentech ...
Tags: Dako, cancer diagnostics solutions, HercepTest, HER2 FISH
Sanofi and Regeneron Pharmaceuticals have received FDA priority review for the biologics license application (BLA) of ZALTRAP (aflibercept) as a treatment for metastatic colorectal cancer (mCRC). The filing was based on the Phase III ...
Lixte Biotechnology, a cancer drug discovery company, has received a notice of allowance from the USPTO for its histone deacetylase inhibitor (HDACi), LB-201, and other structural homologs. Lixte founder and president John Kovach said ...
Tags: USPTO, cancer treatment, clinical technology, pharmaceutical product